Last reviewed · How we verify
Nicorette Mini Lozenge
At a glance
| Generic name | Nicorette Mini Lozenge |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- iCanQuit Smoking Cessation Among Hispanic Adults (PHASE3)
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit (PHASE4)
- Mindfulness-based Smoking Cessation Enhanced With Mobile Technology (NA)
- Take A Break - Rural (NA)
- Health Systems Reach Interventions Project (PHASE4)
- The Options 2 Study (PHASE4)
- Cessation Screening Project (PHASE4)
- Treating Caregivers Who Smoke at AFCH (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicorette Mini Lozenge CI brief — competitive landscape report
- Nicorette Mini Lozenge updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI